INTELLIA THERAPEUTICS INC. - COMMON STOCK

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

27 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

11 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors

05 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

31 May 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

04 May 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

01 May 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates

27 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Names Bill Chase to its Board of Directors

17 Apr 2023 16:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

21 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

02 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

23 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

16 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

11 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

05 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

30 Nov 2022 21:28:58 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

30 Nov 2022 16:36:59 By Nasdaq GlobeNewswire

Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting

12 Nov 2022 16:30:00 By Nasdaq GlobeNewswire

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022

05 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

03 Nov 2022 07:30:01 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

31 Oct 2022 07:30:00 By Nasdaq GlobeNewswire